GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Oct 2017 10:19 AM
RNS
Total Voting Rights
25 Sep 2017 02:57 PM
RNS
Director/PDMR Shareholding
20 Sep 2017 07:00 AM
RNS
Positive IMPACT results for Trelegy in COPD
19 Sep 2017 07:00 AM
RNS
Trelegy Ellipta: FDA approval in COPD received
15 Sep 2017 07:00 AM
RNS
Trelegy Ellipta: positive opinion from CHMP Europe
14 Sep 2017 07:00 AM
RNS
Unanimous FDA approval for Shingrix in over 50s
12 Sep 2017 04:07 PM
RNS
Director/PDMR Shareholding
12 Sep 2017 08:57 AM
RNS
GSK: phase III results on mepo in COPD in NEJM
11 Sep 2017 08:08 AM
RNS
GSK announce positive results from SLS lung study
06 Sep 2017 04:02 PM
RNS
Director/PDMR Shareholding
01 Sep 2017 09:43 AM
RNS
Total Voting Rights
10 Aug 2017 04:43 PM
RNS
Director/PDMR Shareholding
10 Aug 2017 10:50 AM
RNS
Director/PDMR Shareholding
04 Aug 2017 09:06 AM
RNS
Base prospectus re £15bn EMTN programme
01 Aug 2017 11:02 AM
RNS
Total Voting Rights
28 Jul 2017 04:03 PM
RNS
Director/PDMR Shareholding
28 Jul 2017 03:51 PM
RNS
Director/PDMR Shareholding
26 Jul 2017 01:22 PM
RNS
Director/PDMR Shareholding
26 Jul 2017 12:41 PM
RNS
Director/PDMR Shareholding - Replacement
26 Jul 2017 11:00 AM
RNS
Half-year Report
25 Jul 2017 01:30 PM
RNS
ViiV announces results from NEAT 022 study
25 Jul 2017 01:30 PM
RNS
ViiV announces positive results from DAWNING
24 Jul 2017 09:02 AM
RNS
LATTE-2 phII results presented at IAS in Paris
21 Jul 2017 03:34 PM
RNS
Director/PDMR Shareholding
21 Jul 2017 03:30 PM
RNS
Director/PDMR Shareholding
21 Jul 2017 01:59 PM
RNS
GSK submits EU filing for Relvar Ellipta extension
21 Jul 2017 11:00 AM
RNS
Directorate Change
17 Jul 2017 06:08 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:44 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:37 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 05:19 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 04:53 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 04:37 PM
RNS
Director/PDMR Shareholding
17 Jul 2017 02:20 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:58 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:46 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 04:02 PM
RNS
Director/PDMR Shareholding
14 Jul 2017 11:57 AM
RNS
Director/PDMR Shareholding
12 Jul 2017 04:12 PM
RNS
Director/PDMR Shareholding
03 Jul 2017 10:05 AM
RNS
Total Voting Rights
28 Jun 2017 04:13 PM
RNS
GSK announces US filing for mepo in EGPA
27 Jun 2017 10:06 AM
RNS
GSK starts phIII study on mepo for nasal polyps
21 Jun 2017 02:35 PM
RNS
Director/PDMR Shareholding
21 Jun 2017 02:05 PM
RNS
GSK presents Shingrix PhIII study results at ACIP
19 Jun 2017 04:29 PM
RNS
GSK confirms start date for Luke Miels
12 Jun 2017 04:43 PM
RNS
Director/PDMR Shareholding
05 Jun 2017 05:23 PM
RNS
Director/PDMR Shareholding
02 Jun 2017 07:00 AM
RNS
ViiV submits first 2-drug HIV regimen application
01 Jun 2017 10:58 AM
RNS
Total Voting Rights
31 May 2017 04:25 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings